tbuckley/cabot-search huggingface dataset:
Erratum: Corrigendum: The receptor NLRP3 is a transcriptional regulator of TH2 differentiation
Authors: Mélanie Bruchard, Cédric Rebé, Valentin Derangère, Dieudonnée Togbé, Bernhard Ryffel, Romain Boidot, Etienne Humblin, Arlette Hamman, Fanny Chalmin, Hélène Berger, Angélique Chevriaux, Emeric Limagne, Lionel Apetoh, Frédérique Végran, François Ghiringhelli
Journal: Nature Immunology (2015)
The Role of Mucous Cells in the Production of Gastric Neoplasms&lt;xref ref-type="fn" rid="fn1"&gt;&lt;sup&gt;1&lt;/sup&gt;&lt;/xref&gt;&lt;xref ref-type="fn" rid="fn2"&gt;&lt;sup&gt;2&lt;/sup&gt;&lt;/xref&gt;
Authors: Edward L. Howes
Journal: JNCI Journal of the National Cancer Institute (1949)

Journal Article The Role of Mucous Cells in the Production of Gastric Neoplasms Get access Edward L. Howes Edward L. Howes Department of Surgery and Cancer Research, Columbia University, New York Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 10, Issue 2, October 1949, Pages 377–404, https://doi.org/10.1093/jnci/10.2.377 Published: 01 October 1949
PTU-098 An innovative model to increase uptake of hepatitis C testing in the pakistani population in reading, england
Authors: D Linzey, S Shaheen, O Macleod, F Chen, J Booth, A Evans
Journal: Gut (2015)

<h3>Introduction</h3> To evaluate the use of non-medical volunteers to lead community based testing for Hepatitis C in the Pakistani population in Reading, Berkshire, England. Berkshire is a county bordering Greater London with one of the largest Pakistani populations in the UK after London and Birmingham. The Royal Berkshire hospital serves a population of around 600,000 people. <h3>Method</h3> Four female community volunteers from the local Pakistani community were trained to deliver point of care testing for Hepatitis C using oral swabs. they operated within a strict protocol with clear governance, support and training. Individuals for testing self-referred following community based awareness events. Reactive results were followed up with confirmatory PCR tests by the Viral Hepatitis Nurse Consultant and then treated in the Viral Hepatitis clinic at the Royal Berkshire Hospital. <h3>Results</h3> In 18 months the volunteers performed 300 oral tests. 8 tests (2.6%) were reactive for Hepatitis C. Of these 1 (12.5%) returned to Pakistan and was lost to follow up. 1 (12.5%) had spontaneously cleared the virus. The remaining 6 (75%) were initiated on anti-viral treatment. At the time of submission 4 patients (50%) had achieved SVR and the remainder were still on treatment. <h3>Conclusion</h3> There is a recognised higher prevalence of Hepatitis C in the Pakistani population. This group are often regarded as "hard to reach" resulting in late diagnosis and a morbidity associated with this. This project demonstrates the value of community volunteers in identifying patients for treatment who would not normally have presented for testing. <h3>Disclosure of interest</h3> None Declared.
Skeletal Muscle Dysfunction in Chronic Obstructive Pulmonary Disease
Authors: E Berton, R Antonucci, P Palange
Journal: American Journal of Respiratory and Critical Care Medicine (1999)

During the last decade evidence has been accumulated on the role of skeletal muscle dysfunction in reducing exercise capacity and affecting the quality of life of patients with chronic obstructive pulmonary disease (COPD). An appreciable body of research has helped to identify morphological and biochemical alterations, physiological consequences, and possible therapeutic interventions. There are, however, still many areas of uncertainty. For example it is not clear how much of the alterations are within the muscle itself or the consequence of the altered environment in which the muscle works. Similarly it is not clear how much of the impairment is simply due to aging and chronic inactivity. Another key issue is the possible additive effect of drugs often used in COPD patients, such as steroids, beta 2-agonist and cyclosporin. A specific additional layer of complexity comes from nutritional considerations and in particular loss of muscle mass which not infrequently accompanies severe disease and even greater exercise intolerance. Studies on the effects of training or other therapeutic interventions have shown that muscle dysfunction is partially reversible. There is, however, a clear need for studies based on cellular and molecular methods aimed to clarify the role of factors such as oxidative stress, inflammation and nutritional deficiencies on skeletal muscle structure and function. The focus of this review is to highlight the current knowledge on skeletal muscle dysfunction in COPD and briefly summarize the possible therapeutic implications.
Massachusetts Medical Society
Authors: John Figgis Jewett
Journal: New England Journal of Medicine (1973)

COMMITTEE ON MATERNAL WELFARECoagulopathy Syndrome Due to StreptococciA 23-year-old para four was readmitted to the hospital two weeks post partum with hemoptysis and pain, ecchymosis and edema in the right leg.The patient had borne four children normally, most recently after a short stimulated labor. In four uneventful days post partum laboratory tests had included a hemoglobin of 13.5 g per 100 ml and a white-cell count of 11,200. One week after discharge pain developed in the right leg, but she did not speak to her obstetrician. Three days later, at about 11:30 p.m., she called another doctor, . . .
The effect of changing thyroid function on cyclic affective illness in a human subject
Authors: M S Bauer, P C Whybrow
Journal: American Journal of Psychiatry (1986)

Thyroid function abnormalities are common in persons with rapid-cycling bipolar affective illness. Some women who cycle rapidly respond to thyroxine, but there is scant evidence that the people who have thyroid abnormalities are the ones who respond to thyroid treatment. The authors report successful thyroxine treatment of a man whose rapid cycling began and resolved after changes in his thyroid status. The period of his affective cycle was altered by both lithium and thyroxine. The authors suggest that CNS thyroid status may determine the clinical course of some persons with a fixed cycle of affective episodes.
PWE-142 Persistent histological activity in treated aih: prospective evaluation of an enhanced immunosuppression (ei) strategy
Authors: VM Gordon, A Dube, E Mcfarlane, H Dhaliwal, M Karajeh, D Gleeson
Journal: Gut (2015)

<h3>Introduction</h3> We have reported (Hoeroldt 2010; J Hepatol 59:A13) that, of patients with AIH who attain biochemical remission (normal serum transaminases) on standard treatment (Prednisolone plus Azathioprine 1 mg/kg/day), persistent inflammation (Ishak histological activity index (HAI) &gt;3) is found on repeat liver biopsy (biopsy 2) in 40% and is associated with increased long term mortality. We have developed an enhanced immunosuppression (EI) regime in these patients: continuation of Prednisolone and an increased dose of Azathioprine to 2 mg/kg/day (or Mycophenolate (MMF) if Azathioprine intolerant), with repeat biopsy (biopsy 3) after at least 1 year. We aim to assess efficacy of this EI strategy in achieving histological remission. <h3>Method</h3> Assessment of results of biopsy 3 in patients with HAI &gt;3 on biopsy 2 and who then received EI. Comparison with (a) those with HAI &gt;3 on biopsy 2 but who did not receive EI and (b) those in remission (HAI≤3) on biopsy 2 and who had a third biopsy to confirm persistence of remission. Biopsies were assessed by a single Liver Histopathologist (AKD). <h3>Results</h3> All patients had AIH by 1999 International Group criteria. Twenty eight (20 female, age at diagnosis (median (range) 57 (16–75)yr) had persistent inflammation (HAI 5 (4–12)) on biopsy 2 after 26 (17–98) months on standard treatment. Of these, 19 received IE: 13 patients had 2mg/kg and 2 had 1.5mg/kg Azathioprine and 4 had their MMF dose doubled. On biopsy 3, after a further 18 (12–80) months, HAI had fallen from 5 (4–12) to 4 (2–11) (NS (p = 0.436)) but only 6 of the 19 patients (32%) achieved remission (HAI≤3). Ishak fibrosis score was unchanged: 3(0–6) on biopsy 2 vs 3(1–6) on biopsy 3, but the number of patients with cirrhosis increased from 2 to 4. In the remaining 9 patients, not receiving EI, HAI was 5 (4–8) on biopsy 2 and 4(2–11) on biopsy 3, performed 47(16–97) months later (NS (p = 0.836)). 3 patients (33%) achieved remission. In a further 12 patients (11 female, age 44(9–76) yr) who had achieved histological remission on biopsy 2, HAI on biopsy 3, performed 25 (17–85) months later was 2(0–4) and 11 of the 12 (92%) remained in histological remission. <h3>Conclusion</h3> This enhanced immunosuppression regime is of limited efficacy in achieving histological remission in patients with AIH who fail to do so on standard treatment. Such patients may require other therapies. However, if histological remission is achieved on standard therapy, this is usually maintained. <h3>Disclosure of interest</h3> None Declared.
THU0401 Impact of Belimumab Treatment on Quality of Life, Evaluated by Lupusqol Questionnaire, In Patients Affected by Systemic Lupus Erythematosus: Table 1.
Authors: F. Morello, F. Ceccarelli, F.R. Spinelli, L. Massaro, C. Perricone, S. Truglia, F. Miranda, C. Alessandri, F. Conti, G. Valesini
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> Systemic Lupus Erythematosus (SLE) is an autoimmune disease, characterized by periods of remission and flares. Recently, a monoclonal anti-BLyS (<i>B Lymphocyte Stimulator</i>) antibody, Belimumab, has been approved for the treatment of SLE patients with active disease, refractory to conventional therapy. The evaluation of Quality of Life (QoL) is a critical issue in the global assessment of SLE patients, considering the possible influence in the work ability. Recently, LupusQoL questionnaire, specifically designed for SLE patients, has been validated. <h3>Objectives</h3> The aim of the present study was to evaluate the effect of Belimumab treatment on QoL of SLE patients. <h3>Methods</h3> SLE patients (1997 ACR criteria) candidate to start Belimumab treatment were enrolled. Patients received Belimumab 10 mg/kg at baseline, week 2, 4 and then every 4 weeks. According to study protocol, patients underwent physical examination, laboratory assessment and disease activity evaluation using SLEDAI-2K. All patients fulfilled LupusQoL-Italy [1] at the baseline (T0), and then at week 4 (T1), 12 (T2), and 24 (T3). The LupusQoL is a self-administered questionnaire, consisting of 34 questions, classified in 8 domains: Physical Health (PH), Pain (P), Planning (PL), Intimate Relationships (IR), Burden to Others (BO), Emotional Health (EH), Body Image (BI) and Fatigue (F). Answers are recorded according to Likert scale, from 0 (always) to 4 (never). <h3>Results</h3> Eleven female patients were enrolled (mean age ± SD 41.3±10.1 years; mean disease duration ± SD 21.5±14 years). Table 1 shows mean values for each domain of LupusQoL, at each time-point. A statistically significant improvement in all the items was found at T2 except for IR, BI and F. The items P and EH progressively improved at all the time-points evaluated. Items PH, PL and BO showed an improvement from T0 to T2, not maintained at T3. The items PH, P and BO promptly improved after 4 weeks of treatment. <h3>Conclusions</h3> The present study evaluated the effect of Belimumab treatment on QoL of SLE patients using LupusQoL-Italy. After 6 months, most of the items evaluated improved. It is not surprising that the items related with intimate relationship and body image did not improve. Fatigue in SLE is often associated with manifestations including depression and fibromyalgia, which may require a different therapeutic approach. <h3>References</h3> Conti F, Perricone C, Reboldi G, Gawlicki M, Bartosiewicz I, Pacucci V, Massaro L, Miranda F, Truglia S, Alessandri C, Spinelli F, Teh LS, Ceccarelli F, Valesini G. Validation of a disease-specific health-related quality of life measure in adult Italian patients with systemic lupus erythematosus: LupusQoL-IT. Lupus 2014;23: 743-751. <h3>Disclosure of Interest</h3> None declared
Enzymes Proposed as Systemic Anti-Inflammatory Agents
Authors: A L WATNE, R L MONTGOMERY, W W PETTIT
Journal: JAMA (1964)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Cardiovascular safety of methylphenidate among children and young people with attention-deficit/hyperactivity disorder (ADHD): nationwide self controlled case series study
Authors: Ju-Young Shin, Elizabeth E Roughead, Byung-Joo Park, Nicole L Pratt
Journal: BMJ (2016)

To determine whether treatment with methylphenidate in children and young people with attention-deficit/hyperactivity disorder (ADHD) was associated with cardiovascular events. Self controlled case series analysis. Nationwide health insurance database, 1 January 2008 to 31 December 2011, in South Korea. 1224 patients aged ≤17 who had experienced an incident cardiovascular event and had had at least one incident prescription for methylphenidate. A recorded diagnosis (either a primary or secondary cause) of any of the following cardiovascular adverse events: arrhythmias (ICD-10 (international classification of diseases, 10th revision) codes I44, I45, I47, I48, I49), hypertension (codes I10-I15), myocardial infarction (code I21), ischemic stroke (code I63), or heart failure (code I50). Incidence rate ratios were calculated with conditional Poisson regression and adjusted for time varying comorbidity and comedication. Increased risk of arrhythmia was observed in all exposed time periods-that is, periods of treatment with methylphenidate-(incidence rate ratio 1.61, 95% confidence interval 1.48 to 1.74), and the risk was highest in the children who had congenital heart disease. No significant risk of myocardial infarction was observed for all exposed time periods (1.33, 0.90 to 1.98), though risk was higher in the early risk periods between eight and 56 days after the start of treatment with methylphenidate. No significant increased risk was observed for hypertension, ischemic stroke, or heart failure. The relative risk of myocardial infarction and arrhythmias is increased in the early period after the start of methylphenidate treatment for ADHD in children and young people. Though the absolute risk is likely to be low, the risk-benefit balance of methylphenidate should be carefully considered, particularly in children with mild ADHD.
DSM-III axis I diagnoses of Indian psychiatric patients with somatic symptoms
Authors: S Saxena, M K Nepal, D Mohan
Journal: American Journal of Psychiatry (1988)

When DSM-III criteria were applied to 123 Indian psychiatric outpatients with predominantly somatic symptoms, the most common axis I diagnoses were dysthymic disorder (36.6%) and generalized anxiety disorder (11.4%). Thirty-nine percent of the patients fitted only into atypical diagnostic categories.
Paradoxical benefit of increased distance of residence from cancer treatment hospitals (CTH) in the United Kingdom (UK)
Authors: S. M. Crawford, V. Sauerzapf, A. P. Jones, R. Haynes, H. Zhao, D. Forman
Journal: Journal of Clinical Oncology (2007)

6536 Background: UK residents have, through the National Health Service, access via primary care referral to diagnostic and treatment services free of charge. However there is evidence of uneven uptake by cancer patients. Methods: We have undertaken a cancer registry based study relating socioeconomic characteristics of the patient's place of residence and travel to CTH to uptake and outcome. We report here these relationships according to whether patients underwent any surgery, radiotherapy or chemotherapy. Results: The Table shows the number of patients by site and the percentage receiving any of the specified treatments. Against each deprivation quartile defined by the index of multiple deprivation (DQ1 is least deprived) is given the odds ratio (95% confidence interval) by logistic regression analysis of receiving treatment as it increases with each minute of travel time between home and hospital after allowing for age, sex, and whether or not the CTH was a specialised cancer centre plus site in bowel and lung cancer type. The tendency for odds ratios to be greater with increasing deprivation is significant (Kendall concordance = 0.6417, p=0.022). Conclusions: We observed an increase in treatment activity with increasing travel time to the CTH when a ‘distance decay’ effect was expected. We hypothesise that this relates to the difficulties of providing primary care in the deprived urban areas in which most CTH are situated. Higher odds ratios for more deprived people suggest that the distance advantage compensates for the effect of deprivation. No significant financial relationships to disclose. [Table: see text]
AB1165 Effectiveness of Nursing Consultations in Rheumatology: Results from the Score Study
Authors: R. Almodovar, A. Fernandez Nebro, L.A. Gracia Perez, J.A. Román Ivorra, J.R. Rodríguez Cros, J. del Pino Montes, A. Rodríguez-Serrano, S. Muñoz-Fernández
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> Nursing Consultations in Rheumatology (NCR) are organizational care models that provide care centred on the rheumatology patient within the scope of a nurse9s abilities. <h3>Objectives</h3> To analyze the effectiveness and quality of care of NCR. <h3>Methods</h3> National multicenter observational prospective cohort study one year follow-up, comparing patients attending rheumatology services with and without NCR. NCR was defined by the presence: 1) Office itself; 2) at least one dedicated nurse, albeit part-time; 3) own agenda citation; and 4) phone. Variables included were (baseline, 6 and 12 months): a) Clinical activity, research and training, infrastructure of unit and resources of NCR); b) Socio-demographics, work productivity (WPAI), assessment of rheumatic disease, use of services and treatments, quality of life, knowledge of the disease and treatment and perceived quality of care. <i>Analysis:</i> Chi square, Fischer9s test, t-Student test, Mann–Whitney U test, Wilcoxon and McNemar9s tests were used. <h3>Results</h3> A total of 393 patients were included: 181NCR and 212 not NCR, corresponding to 39 units, 21 with NCR and 18 without NCR (age 53±11,8 vs 56±13,5 years); females 70% vs 61% and AR 78.5% vs 75,5%. Statistically significant differences were found in patients attended in sites without NCR for the following parameters: higher CRP level (5.9±8.3 vs 4.8±7.8; p&lt;0.005), global disease patient VAS (3.6±2.3 vs 3.1±2.4), physician VAS (2.9±2.1 vs 2.3±2.1; p&lt;0.05) and use of primary care consultations (2.7±5.4 vs 1.4±2.3; p&lt;0.001), worse work productivity, knowledge of the disease, treatment adherence and perceived quality. There were no significant differences in the other parameters between the two groups. <h3>Conclusions</h3> The presence of NCR in the Rheumatology unit contributes to a lower frequency of primary care consultations, improves clinical outcomes and quality of life of patients with rheumatic diseases, also the knowledge of the disease, leading to an improvement of patient adherence to treatment and perceived quality of care. <h3>Disclosure of Interest</h3> None declared
Snatching defeat from the jaws of Pyrrhic victory
Authors: Andy Cowper
Journal: BMJ (2016)

The classicists among BMJ readers will already know that a Pyrrhic victory costs the winner so highly that it is all but a defeat. This is a lesson that both the BMA junior doctors’ committee (JDC) leadership and the health secretary for England, Jeremy Hunt, have learnt the hard way.

After all the rhetoric—#timetotalkJeremy (JDC) and (Hunt’s) “the matter is closed”1—further negotiation was, in the end, possible.2

Indeed, after a few days’ talks, they did the deal3 that the JDC now recommends—and it’s not massively different4 from the previous “to be imposed” deal.5

Most importantly for the government and NHS leaders fighting to keep finances upright, the agreement they reached remained “cost neutral.”

The collateral damage to both …
AB0854 The Prevalence of Secondary Osteoarthritis of the Knee in Patients with Rheumatoid Arthritis
Authors: I. Starodubtseva, L. Vasilieva, A. Nikitin, N. Barsukova
Journal: Annals of the Rheumatic Diseases (2015)

<h3>Background</h3> Among the complications in patients with RA often can be found secondary osteoarthritis, atherosclerosis, systemic osteoporosis<sup>1,2</sup>. <h3>Objectives</h3> The aim of the study was to estimate the prevalence of secondary osteoarthritis of the knee in patients with rheumatoid arthritis and to reveal it association with the parameters of basic disease. <h3>Methods</h3> 565 RA patient9s histories (diagnosis according to the criteria of ACR/EULAR) from the rheumatology in-patient clinic with the mean age 48.4±10, 85.4% female and duration of the disease 3-15 years were reviewed. The features of secondary OA of the knee in patients with RA were assessed with the use of questioning (clinical symptoms, anamnesis of the disease), examination (ultrasonography (US) and X-ray of the joints). <h3>Results</h3> We revealed secondary OA of the knee in 71% of patients with RA. Secondary OA was diagnosed predominantly in anti-CCP pos. patients (68,6%), with DAS 28&gt;5,3 (in present and in the anamnesis) and with the duration of the disease 7-15 years. The more statistical significant associations were observed between DAS 28 and US, X-ray (corr. r=0,734, p&lt;0,01), the duration of the disease and US and X-ray (r=0,671, p&lt;0,05), US, X-ray and morning stiffness (r=0,526, p&lt;0,05). <h3>Conclusions</h3> These findings demonstrate the high prevalence of secondary osteoarthritis of the knee in patients with rheumatoid arthritis. This comorbid medical condition associates with the increase of activity, morning stiffness and duration of underlying disease (RA). <h3>References</h3> Peat G, et al. Clinical classification criteria for knee osteoarthritis; performance in the general population and primary care. Ann Rheum Dis 2006;65:1363–1367. Michaud K, Wolfe F. Comorbidities in rheumatoid arthritis. Best Practice &amp; Res Clin Rheumatol 2007;21:885–906. <h3>Disclosure of Interest</h3> None declared
Molecular Characterization of 11q Deletions Points to a Pathogenic Role of the ATM Gene in Mantle Cell Lymphoma
Authors: Stephan Stilgenbauer, Dirk Winkler, German Ott, Claudia Schaffner, Elke Leupolt, Martin Bentz, Peter Möller, Hans K. Müller-Hermelink, Michael R. James, Peter Lichter, Hartmut Döhner
Journal: Blood (1999)